Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Safety and Immunogenicity of a Recombinant Parvovirus B19 Vaccine Formulated with MF59C.1

2003; Oxford University Press; Volume: 187; Issue: 4 Linguagem: Inglês

10.1086/368382

ISSN

1537-6613

Autores

W. Ripley Ballou, Jennifer L. Reed, W. C. Noble, Neal S. Young, Scott Koenig,

Tópico(s)

Dermatological and COVID-19 studies

Resumo

A recombinant human parvovirus B19 vaccine (MEDI-491; MedImmune) composed of the VP1 and VP2 capsid proteins and formulated with MF59C.1 adjuvant was evaluated in a randomized, double-blind, phase 1 trial. Parvovirus B19–seronegative adults (n=24) received either 2.5 or 25 μg MEDI-491 at 0, 1, and 6 months. MEDI-491 was safe and immunogenic. All volunteers developed neutralizing antibody titers that peaked after the third immunization and were sustained through study day 364

Referência(s)